Tirzepatide
Dual-action peptide for significant weight loss
- Weight Loss/Fat Loss (GLP-1/GIP dual agonist)
Thyroid C-cell tumor risk: Contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN2 syndrome (based on rodent studies; human relevance uncertain) Pancreatitis: Discontinue promptly if pancreatitis is suspected; do not restart if confirmed Gastroparesis: May significantly delay gastric emptying; inform anesthesiologists before procedures Muscle loss: Combine with resistance training to preserve lean mass during weight loss Mental health monitoring: Monitor for depression and suicidal ideation, particularly in patients with history of psychiatric conditions
Mechanism of Action
Tirzepatide is a dual agonist that activates both GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. By engaging both incretin pathways simultaneously, it enhances insulin secretion in a glucose-dependent manner, suppresses glucagon release, slows gastric emptying, and acts on brain appetite centers to reduce food intake and promote satiety. Key Pathways: GLP-1 receptor activation (appetite suppression, insulin secretion, delayed gastric emptying), GIP receptor activation (enhanced insulin response, potential effects on fat metabolism), Central nervous system satiety signaling via hypothalamic pathways The dual incretin mechanism produces substantial weight loss (studies show mean losses of 15-23% body weight) along with improvements in glycemic control, lipid profiles, and blood pressure. Real-world data demonstrate dose-dependent reductions in BMI, waist circumference, and metabolic markers including fasting glucose, insulin resistance, and triglycerides.
Common Dose Reference Ranges
Educational reference ranges only — discuss actual dosing with a qualified healthcare provider.
Full Tirzepatide protocols — frequency, timing, cycle length, reconstitution & research
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Gastroparesis risk / delayed gastric emptying
- Pancreatitis
- Thyroid C-cell tumors (rodent studies)
- Muscle mass loss without resistance training